Advertiser / Brand
AbbVie vs Royal Philips
Structured technology and market comparison · 2026
Direct Feature Comparison
AbbVie · vs · Royal PhilipsBiopharmaceutical company developing and commercialising prescription medicines.
Dutch health technology company serving providers and consumers.
Analyze all overlapping signals and tech stacks for AbbVie and Royal Philips
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between AbbVie and Royal Philips?
When comparing AbbVie and Royal Philips, both platforms operate within the Advertiser / Brand ecosystem. AbbVie is positioned as Biopharmaceutical company developing and commercialising prescription medicines, whereas Royal Philips focuses on Dutch health technology company serving providers and consumers. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to AbbVie and Royal Philips?
When evaluating AbbVie and Royal Philips, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of AbbVie and Royal Philips compare?
AbbVie is headquartered in US (founded in 2012) with >5,000 employees. Royal Philips is based in NL (founded in 1891) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: AbbVie vs Royal Philips
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
AbbVie
Recent Signals
- ·AbbVie
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...
- ·AbbVie
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...
- ·AbbVie
AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...
Royal Philips
Recent Signals
- ·SEC APIfinancials
6-K Financial Filing Analysis for Royal Philips (2026-07-28)
Koninklijke Philips N.V. reported solid Q2 2026 financial results with group sales reaching EUR 4.36 billion, reflecting 4% comparable sales growth driven by improvements across all business segments. Income from operations increased significantly to EUR 609 million and Adjusted EBITA rose to EUR 717 million (16.4% margin), bolstered by an effective 4.2% (EUR 186 million) benefit from US tariff refunds. Net income reached EUR 386 million, up from EUR 240 million in Q2 2025. Following the recovery of US import duties, Philips upgraded its full-year 2026 Adjusted EBITA margin outlook to 13.5%-14.0% (previously 12.5%-13.0%) and increased its Free Cash Flow guidance to EUR 1.5-1.7 billion (previously EUR 1.3-1.5 billion), while reiterating comparable sales growth guidance of 3.0%-4.5%.
- Q2 2026 sales reached EUR 4,360,000,000 (+4% comparable sales growth), with net income increasing 60.8% YoY to EUR 386,000,000.
- Adjusted EBITA increased to EUR 717,000,000 (16.4% margin), including a EUR 186,000,000 US tariff refund benefit.
- Full-year 2026 outlook updated: Adjusted EBITA margin raised to 13.5%-14.0% and Free Cash Flow raised to EUR 1.5-1.7 billion; comparable sales growth reaffirmed at 3%-4.5%.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners AbbVie and Royal Philips share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks